Bispecific Therapy: Advancing Patient Care through Targeted Treatment
March 11, 2025
Format
Interactive, Live Virtual Webinar
Target Audience
This activity is intended for physicians, physician assistants/associates, and nurses engaged in the care of patients with hematologic malignancies.
Educational Objectives
At the conclusion of this activity, participants will be better able to:
- Describe the underlying science and mechanisms of bispecific therapies
- Identify current and emerging indications for bispecific therapies for hematologic malignancies
- Assess the clinical evidence on the efficacy, safety, and potential side effects of bispecific therapies
- Develop strategies for incorporating bispecific therapies into clinical practice
- Describe the treatment process and mechanisms to improve patient understanding, care, and involvement
- Discuss challenges and potential future advancements in bispecific antibody development
Faculty
Luciano Costa, MD, PhD
Professor of Medicine
Mary and Bill Battle Professor of Multiple Myeloma
The University of Alabama at Birmingham
Birmingham, AL
Elise Curry, BA, BSN, RN, OCN
Clinical Trial Nurse Navigator
Clinical Trial Support Center
The Leukemia & Lymphoma Society
Washington, DC
Peter Martin, MD
Professor of Medicine
Chief of the Lymphoma Program
Weill Cornell Medicine
New York, NY
Continuing Education Information
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The Leukemia & Lymphoma Society. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
Approval for Nurses has been obtained by The Leukemia & Lymphoma Society under provider number 50-12996, Expires: 10/31/2026, to award 1.0 continuing education contact hour through the Florida Board of Nursing.
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.
Method of Participation
Learners must participate in the entire activity and complete and submit the evaluation form to earn credit. Once completed, the certificate will be generated. If you have questions regarding the receipt of your certificate, please contact us via email at ProfEducation@LLS.org.
There are no fees for participating in or receiving credits for this activity.
Providers
This activity is jointly provided by The Leukemia & Lymphoma Society and Postgraduate Institute for Medicine.
Supporters
There is no commercial support associated with this activity.
Disclosure of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
- Luciano Costa reports Grant/Research Support from BMS, Johnson & Johnson, Pfizer, AbbVie, Caribou, Genentech, and Gracel, and Consultant/Advisory Board for BMS, Johnson & Johnson, Pfizer, AbbVie, Caribou, Genentech, Regeneron, Adaptive Biotechnologies, and Astra Zeneca.
- Peter Martin reports Consultant/Advisory Board for Abbvie, AstraZeneca, Beigene, BMS, Genentech, Janssen, Pepromene, and Merck
- Elise Curry reports Patient advisory board member for Viracta Pharmaceuticals with compensation provided to LLS.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: ProfEducation@LLS.org.